Recurrent Verrucous Carcinoma of the Larynx Completed Phase Trials for Gefitinib (DB00317)

Also known as: Laryngeal verrucous carcinoma recurrent / Recurrent Laryngeal Verrucous Carcinoma / Squamous Cell Carcinoma of the Larynx / Laryngeal squamous cell carcinoma / Primary squamous cell carcinoma of larynx (disorder) / Squamous cell carcinoma of larynx (disorder)

DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)CompletedNot Available IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment